our Premium Content: News alerts, weekly reports and conference planners

GENE:

PTK2 (Protein Tyrosine Kinase 2)

News alerts, weekly reports and conference planners

13d

Talin-1, Vinculin, and FAK Expressions are Associated With Clinicopathological Behavior in Colorectal Cancer. (PubMed, Appl Immunohistochem Mol Morphol)

Low talin-1 and vinculin expressions and high FAK expression correlated with aggressive clinicopathological behaviors and poor overall survival in patients with CRC. Low talin-1 expression was identified as an independent poor prognostic factor and may be a useful therapeutic target in patients with CRC.

13 days ago

Journal

TLN1 (Talin 1) • VCL (Vinculin) • PTK2 (Protein Tyrosine Kinase 2)

14d

Integrative multi-omics and experimental analyses implicate PTK2 as a lorazepam-associated biomarker and potential therapeutic target in ovarian cancer. (PubMed, Front Pharmacol)

PTK2 functions as a biomarker and druggable target that integrates tumor growth, immune modulation, and metabolic adaptation. Targeting PTK2 may provide a promising therapeutic strategy for precision oncology and rational drug repurposing.

14 days ago

Journal

PTK2 (Protein Tyrosine Kinase 2)

19d

IS THERE A PROGNOSTIC ROLE OF FOCAL ADHESION KINASE AND CD8 IN SQUAMOUS CELL HEAD AND NECK CANCER TREATED WITH RADIOTHERAPY? (PubMed, Acta Clin Croat)

Patients with low expression of FAK had significantly less relapses. The prognostic role of FAK and CD8 expression in SCHNC patients treated with radiotherapy was not proven.

19 days ago

Journal

CD8 (cluster of differentiation 8) • PTK2 (Protein Tyrosine Kinase 2)

23d

Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis. (PubMed, Sci Adv)

Pharmacological inhibition of FAK with single agent VS-4718 did not significantly reduce macroscopic tumor volume; however, its use in combination with the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib resulted in both a significant reduction in tumor volume and the preservation of dorsal root ganglion architecture. Our findings establish a critical role for FAK in schwannoma development and provide rationale for evaluation of combination FAK plus MEK inhibition in future clinical trials for NF2-associated SWN.

23 days ago

Preclinical • Journal

HGF (Hepatocyte growth factor) • NF2 (Neurofibromin 2) • NLRC5 (NLR Family CARD Domain Containing 5) • PTK2 (Protein Tyrosine Kinase 2)

Koselugo (selumetinib) • VS-4718

27d

Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers for Recurrence and Progression Risk. (PubMed, J Proteome Res)

Our study identified specific proteins as potential NMIBC biomarkers and drug targets. The identified proteins, particularly those linked to tumor recurrence and staging, warrant further validation to assess their clinical utility in NMIBC diagnosis, prognosis, and treatment strategies.

27 days ago

Journal

KRT7 (Keratin-7) • AGR2 (Anterior gradient 2) • CTSD (Cathepsin D) • PTK2 (Protein Tyrosine Kinase 2) • SPINT1 (Serine Peptidase Inhibitor, Kunitz Type 1)

2ms

Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma. (PubMed, Sci Rep)

MRTX1133 induced alterations associated with mesenchymal-to-epithelial transition; furthermore, lower levels of activated Erk, altered FAK expression, and activation were observed. In addition to the antiproliferative effects of MRTX1133, our in vitro and in vivo results indicate the importance of MRTX1133 as a potential antimetastatic drug in PDAC therapy.

2 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • PTK2 (Protein Tyrosine Kinase 2)

KRAS mutation • KRAS G12D

MRTX1133

2ms

Propofol suppresses esophageal cancer tumorigenesis by modulating circular RNA protein tyrosine kinase 2/microRNA-134-5p/poly ADP-ribose polymerase 9 axis. (PubMed, J Biochem Mol Toxicol)

Propofol exerted an antitumor role in EC advancement at least partly through the circ-PTK2/miR-134-5p/PARP9 axis, providing new insight into the involvement of circRNAs in propofol-mediated effect on EC progression. This study also provides evidence that circ-PTK2 could be developed as a potential therapeutic target for EC patients.

2 months ago

Journal • PARP Biomarker

PARP1 (Poly(ADP-Ribose) Polymerase 1) • TYK2 (Tyrosine Kinase 2) • PTK2 (Protein Tyrosine Kinase 2) • MIR134 (MicroRNA 134)

4ms

CTTN overexpression in HNSCC inhibits Anoikis-apoptosis. (PubMed, Sci Rep)

Furthermore, we found that inhibiting the apoptosis-related gene CTTN suppresses the anti-apoptotic capacity of HNSCC. Results from HNSCC-PDOs suggest that CTTN may represent a key target for HNSCC invasion and treatment.

4 months ago

Journal

TTN (Titin) • SPP1 (Secreted Phosphoprotein 1) • PLK1 (Polo Like Kinase 1) • MAPK1 (Mitogen-activated protein kinase 1) • SLCO1B3 (Solute carrier organic anion transporter family member 1B3) • CEACAM1 (CEA Cell Adhesion Molecule 1) • SFRP1 (Secreted frizzled related protein 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • CTTN (Cortactin) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2 ) • PLAU (Plasminogen Activator) • PTK2 (Protein Tyrosine Kinase 2) • SPHK1 (Sphingosine Kinase 1)

4ms

Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer. (PubMed, Breast Cancer)

FAK inhibition was shown to suppress non-angiogenic vascularization. Defactinib has the potential to serve as a novel treatment for malignant breast cancer which is resistant to conventional therapies.

4 months ago

Journal

PTK2 (Protein Tyrosine Kinase 2)

Fakzynja (defactinib)

5ms

C1QBP forms a positive feedback loop with the PAICS/FAK/C-MYC axis to promote cancer cell proliferation. (PubMed, Oncogene)

In vivo experiments confirmed its ability to provide prolonged and stable C1QBP inhibition along with enhanced antitumor efficacy. In conclusion, our study suggests that C1QBP may serve as a valuable biomarker for tumour prognosis and that silencing C1QBP using HA gel-siC1QBP -either alone or combined with targeted/ immunotherapies -represents a promising therapeutic strategy against tumors.

5 months ago

Journal • IO biomarker

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PAICS (Phosphoribosylaminoimidazole Carboxylase And Phosphoribosylaminoimidazolesuccinocarboxamide Synthase) • PTK2 (Protein Tyrosine Kinase 2)

5ms

The role of focal adhesion kinase in bladder cancer: translation from in vitro to ex vivo human urothelial carcinomas. (PubMed, Radiol Oncol)

To our knowledge, this is the first report demonstrating the role of FAK and its inhibition across both normal and cancerous bladder urothelial models. This study highlights the critical role of FAK in the progression of human bladder cancer and establishes a foundation for exploring FAK inhibition as a potential therapeutic approach in bladder cancer treatment.

5 months ago

Preclinical • Journal

CASP3 (Caspase 3) • PTK2 (Protein Tyrosine Kinase 2)

Fakzynja (defactinib) • VS-4718 • PF-573228

5ms

The study underscores the prognostic relevance of ARGs in skin melanoma and their contribution to tumor immunity. Overall, our findings expand our understanding of melanoma immunogenetics, suggesting the use of angiogenesis-related genes not merely as vascular regulators, but also as immune modulators.

5 months ago

Journal

SPP1 (Secreted Phosphoprotein 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • COL3A1 (Collagen Type III Alpha 1 Chain) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • COL5A2 (Collagen Type V Alpha 2 Chain) • PTK2 (Protein Tyrosine Kinase 2) • S100A4 (S100 calcium binding protein A4)